

## PHASE 2 Asthma Studies - ISS Opportunity Notice #4272

ISS is working with a CRO and seeking sites for randomized, double-blind, placebo-controlled, phase 2 studies for patients with asthma.

### Site Requirements:

- Previous moderate to severe asthma trial experience.

### Additional details:

- Start Date: October/November 2023
- Patient enrollment: TBD
- Location: US
- Design:
  - Enrollment period: 10.5 months.
  - IP is a clinical-stage monoclonal antibody administered via subcutaneous injection.
- Notable inclusion criteria include:
  - Adults (18-75 years old) with moderate to severe asthma.

Next steps: **The study team will review ISS site list, and approved sites will move forward with a Potential Investigator Questionnaire (PIQ).**

Study opportunity deadline: **ASAP**

**If your site would like to submit multiple PIs, please complete a separate set of questions for each PI.**

Interested in this study?

[Yes](#)

[No](#)

This message was sent by Investigator Support Services, 21 E Huron Street, #802, Chicago, IL 60611.  
CONFIDENTIALITY NOTICE: The information contained in this communication is confidential and does not apply to anyone other than the intended recipient. If the reader of this communication is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you no longer want to receive study referrals from ISS, please unsubscribe here. [Unsubscribe from ISS Network](#)